C. Sarrazin, The importance of resistance to direct antiviral drugs in HCV infection in clinical practice, J Hepatol, vol.64, pp.486-504, 2016.

J. M. Pawlotsky, Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens, Gastroenterology, vol.151, pp.70-86, 2016.

S. Elmasry, S. Wadhwa, and B. R. Bang, Detection of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation, Gastroenterology, 2016.

T. J. Liang and M. G. Ghany, Current and future therapies for hepatitis C virus infection, N Engl J Med, vol.368, pp.1907-1924, 2013.

F. Zoulim, T. J. Liang, and A. L. Gerbes, Hepatitis C virus treatment in the real world: optimising treatment and access to therapies, Gut, vol.64, pp.1824-1857, 2015.

M. P. Curry, J. G. O'leary, and N. Bzowej, Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis, N Engl J Med, vol.373, pp.2618-2646, 2015.

R. T. Chung and T. F. Baumert, Curing chronic hepatitis C--the arc of a medical triumph, N Engl J Med, vol.370, pp.1576-1584, 2014.

D. J. Felmlee, A. Coilly, and R. T. Chung, New perspectives for preventing hepatitis C virus liver graft infection, Lancet Infect Dis, vol.16, pp.735-780, 2016.

M. P. Curry, X. Forns, and R. T. Chung, Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study, Gastroenterology, vol.148, pp.100-107, 2015.

B. R. Englum, A. M. Ganapathi, and P. J. Speicher, Impact of donor and recipient hepatitis C status in lung transplantation, Organ Procurement and Transplant Data, vol.35, pp.228-263, 2016.

P. Pileri, Y. Uematsu, and S. Campagnoli, Binding of hepatitis C virus to CD81, Science, vol.282, pp.938-979, 1998.

E. Scarselli, H. Ansuini, and R. Cerino, The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus, EMBO J, vol.21, pp.5017-5042, 2002.

M. J. Evans, T. Von-hahn, and D. M. Tscherne, Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry, Nature, vol.446, pp.801-806, 2007.

J. Lupberger, M. B. Zeisel, and F. Xiao, EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy, Nat Med, vol.17, pp.589-95, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00705829

B. Sainz, N. Barretto, and D. N. Martin, Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor, Nat Med, vol.18, pp.281-286, 2012.

Q. Li, C. Sodroski, and B. Lowey, Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition, Proc Natl Acad Sci, vol.113, pp.7620-7625, 2016.

P. Meuleman, J. Hesselgesser, and M. Paulson, Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo, Hepatology, vol.48, pp.1761-1769, 2008.

K. Vercauteren, N. Van-den-eede, and A. A. Mesalam, Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents, Hepatology, vol.60, pp.1508-1526, 2014.

I. Fofana, S. E. Krieger, and F. Grunert, Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes, Gastroenterology, vol.139, pp.953-64, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00741442

L. Mailly, F. Xiao, and J. Lupberger, Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody, Nat Biotechnol, vol.33, pp.549-54, 2015.

R. Paciello, R. A. Urbanowicz, and G. Riccio, Novel human anti-Claudin 1 monoclonal antibodies inhibit HCV infection and may synergize with anti-SRB1 mAb, J Gen Virol, vol.97, pp.82-94, 2015.

M. Yamashita, M. Iida, and M. Tada, Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus, J Pharmacol Exp Ther, vol.353, pp.112-130, 2015.

S. He, B. Lin, and V. Chu, Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection, Sci Transl Med, vol.7, pp.282-331, 2015.

F. Xiao, I. Fofana, and C. Thumann, Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C, Gut, vol.64, pp.483-94, 2015.

F. Xiao, I. Fofana, and L. Heydmann, Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents, PLoS Pathog, vol.10, p.1004128, 2014.

A. Zheng, F. Yuan, and Y. Li, Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus, J Virol, vol.81, pp.12465-71, 2007.

L. Meertens, C. Bertaux, and L. Cukierman, The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus, J Virol, vol.82, pp.3555-60, 2008.

S. Haid, C. Grethe, and M. T. Dill, Isolate-dependent use of claudins for cell entry by hepatitis C virus, Hepatology, vol.59, pp.24-34, 2014.

I. Fofana, L. Zona, and C. Thumann, Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies, J Virol, vol.87, pp.10405-10415, 2013.

S. E. Krieger, M. B. Zeisel, and C. Davis, Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations, Hepatology, vol.51, pp.1144-57, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00705657

E. A. Kabat and T. T. Wu, Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites, J Immunol, vol.147, pp.1709-1728, 1991.

P. T. Jones, P. H. Dear, and J. Foote, Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, vol.321, pp.522-527, 1986.

M. Verhoeyen, C. Milstein, and G. Winter, Reshaping human antibodies: grafting an antilysozyme activity, Science, vol.239, pp.1534-1540, 1988.

C. J. Mee, H. J. Harris, and M. J. Farquhar, Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells, J Virol, vol.83, pp.6211-6232, 2009.

J. M. Pestka, M. B. Zeisel, and E. Blaser, Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C, Proc Natl Acad Sci, vol.104, pp.6025-6055, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00395910

S. Fafi-kremer, I. Fofana, and E. Soulier, Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation, J Exp Med, vol.207, pp.2019-2050, 2010.

G. Koutsoudakis, A. Kaul, and E. Steinmann, Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses, J Virol, vol.80, pp.5308-5328, 2006.

J. Witteveldt, M. J. Evans, and J. Bitzegeio, CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells, J Gen Virol, vol.90, pp.48-58, 2009.

M. N. Prichard and C. Shipman, A three-dimensional model to analyze drug-drug interactions, Antiviral Res, vol.14, pp.181-205, 1990.

D. F. Mercer, D. E. Schiller, and J. F. Elliott, Hepatitis C virus replication in mice with chimeric human livers, Nat Med, vol.7, pp.927-960, 2001.

J. R. Scalea, R. N. Barth, and R. Munivenkatappa, Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts, Transplantation, vol.99, pp.1192-1198, 2015.

P. P. Reese, P. L. Abt, and E. A. Blumberg, Transplanting hepatitis C-positive kidneys, N Engl J Med, vol.373, pp.303-308, 2015.